Photo of Myriam Chalabi from eurekalert.org
Jun 7, 2024, 14:08
Mark Lewis: Myriam Chalabi reporting the NICHE-2 trial in NEJM
Mark Lewis shared on X: .
“TLC: don’t go chasing waterfalls
Myriam Chalabi reporting the NICHE-2 trial with 95% of locally advanced, mismatch repair-deficient colon cancer responding (pathologically!) to neoadjuvant immunotherapy in NEJM.”
Source: Mark Lewis/X
Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 09:55
Nov 21, 2024, 09:28
Nov 21, 2024, 09:23
Nov 21, 2024, 09:04
Nov 21, 2024, 06:49